Follow the Money

...WHO profits from FLU?...

Specialty drug and medical device maker Baxter International Inc. (BAX) on Thursday said its second quarter profit jumped 8%, as higher margins offset lower sales.

The company said that its swine flu vaccination, which is still in development, should be ready to ship later this year, and could boost its full-year revenue by $30 to $40 million.

Deerfield, Illinois-based Baxter reported second quarter net income of $587 million, or 96 cents per share, compared with $544 million, or 85 cents per share, in the year-ago period. Sales in the quarter fell 2% to $3.12 billion from $3.19 billion last year.

Baxter International Inc. (BAX) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars...